Hello, and welcome to our blog! Our blog is inspired by Oleena™, the first digital therapeutic in oncology for patients and their care teams, created by Voluntis.
Patients with cancer often experience distressing symptoms that impair daily functioning and quality of life. When manageable symptoms are left untreated or undertreated, they can lead to treatment interruptions, unscheduled ER visits and hospitalizations. New approaches based on the combination of self-management and remote monitoring have the potential to enhance the quality of care in oncology, improve clinical outcomes and reduce costs for health systems.The purpose of our blog is to share valuable information related to the many facets of cancer care and management, with a focus on symptom self-management, patient activation, care coordination, digital innovations, remote monitoring, and many more.
We hope to inform and connect with the cancer community, especially all types of providers that care for cancer patients and those involved in running a practice that provides cancer care.
Our blog will be a collaboration of different contributors, both from within Voluntis, including members of our Oncology Medical Affairs team, as well as occasional guest bloggers.
Thanks for coming along on this journey with us! Make sure to subscribe to our blog for the latest updates. If you have any topic ideas, feedback or questions, please contact us at firstname.lastname@example.org.
To find more information about Oleena, visit the main website.
Voluntis creates digital therapeutics that empower people suffering from chronic conditions to self- manage their treatment every day. Combining mobile and web apps, Voluntis’ solutions deliver personalized recommendations to the patient and the care team so that they can, for example, adjust treatment dosage, manage side effects or monitor symptoms. These real- time recommendations are based on digitized clinical algorithms. Leveraging its Theraxium technology platform, Voluntis has designed and markets multiple digital therapeutics, especially in diabetes and oncology. Voluntis has long-standing partnerships with leading life science companies. Based out of Boston and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance. For more information, please visit: www.voluntis.com.
Voluntis successfully completed a U.S. Food and Drug Administration (FDA) regulatory review of its Oleena™ software for oncology-related symptoms management and remote patient monitoring. Oleena™ is a Class II medical device under FDA enforcement discretion.